Patients With Follicular Lymphoma (Fl) in Maintained Complete Response (Cr) at 30 Months Show a Survival Similar to a Sex‐ and Age‐matched Spanish General Population

Abstract

No significant difference in OS was observed between the 2 groups for patients not having received rituximab in first line. These data suggest that among patients treated with rituximab, despite an identical PFS, survival outcomes were statistically higher in the <40 group compared to 40-60.Conclusions: This study reports the clinical characteristics and outcomes in the most important cohort of young patients aged <40 with first-line FL. Age <40 y did not appear to influence the treatment outcome, but was associated with a significantly longer OS.

Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era

“…Similar results described in other series confirmed that the outcome of patients who progress early is very unfavourable (Jurinovic et al, 2016) (Maurer et al, 2016). Conversely, more recently, we observed that patients in CR after the maintenance period, at 30 months from the start of therapy, had a remarkably favourable OS, similar to that of the general population (Magnano et al, 2017). The data herein presented are a confirmation of the same tendency along the course of the disease: the shorter the RD, the shorter the survival at any phase of the disease.…”